Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 18(23): 6093-6, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-18954983

ABSTRACT

We report the identification of KD5170, a potent mercaptoketone-based Class I and II-histone deacetylase inhibitor that demonstrates broad spectrum cytotoxic activity against a range of human tumor-derived cell lines. KD5170 exhibits robust and sustained histone H3 hyperacetylation in HCT-116 xenograft tumors following single oral or i.v. dose and inhibition of tumor growth following chronic dosing.


Subject(s)
Antineoplastic Agents/pharmacology , Enzyme Inhibitors/pharmacology , Histone Deacetylase Inhibitors , Prodrugs/pharmacology , Pyridines/pharmacology , Sulfonamides/pharmacology , Animals , Antineoplastic Agents/chemistry , Cell Line, Tumor , Drug Screening Assays, Antitumor , HCT116 Cells , Humans , Inhibitory Concentration 50 , Mice , Mice, Nude , Molecular Structure , Prodrugs/chemistry , Pyridines/chemistry , Structure-Activity Relationship , Sulfonamides/chemistry , Xenograft Model Antitumor Assays
2.
Bioorg Med Chem Lett ; 18(24): 6482-5, 2008 Dec 15.
Article in English | MEDLINE | ID: mdl-18954984

ABSTRACT

In an effort to discover novel non-hydroxamic acid histone deacetylase (HDAC) inhibitors, a novel alpha-mercaptoketone was identified in a high-throughput screen. Lead optimization of the screening hit, led to a number of potent HDAC inhibitors. In particular, alpha-mercaptoketone 19y (KD5150) exhibited nanomolar in vitro activity and inhibition of tumor growth in vivo.


Subject(s)
Drug Screening Assays, Antitumor , Histone Deacetylase Inhibitors , Ketones/chemistry , Antineoplastic Agents/therapeutic use , Chelating Agents/pharmacology , Chemistry, Pharmaceutical , Drug Design , Enzyme Inhibitors/pharmacology , HeLa Cells , Humans , Models, Chemical , Neoplasms/drug therapy , Prodrugs/chemistry , Structure-Activity Relationship , Zinc/chemistry
3.
Mol Cancer Ther ; 7(5): 1054-65, 2008 May.
Article in English | MEDLINE | ID: mdl-18483295

ABSTRACT

Histone deacetylase (HDAC) inhibitors have garnered significant attention as cancer drugs. These therapeutic agents have recently been clinically validated with the market approval of vorinostat (SAHA, Zolinza) for treatment of cutaneous T-cell lymphoma. Like vorinostat, most of the small-molecule HDAC inhibitors in clinical development are hydroxamic acids, whose inhibitory activity stems from their ability to coordinate the catalytic Zn2+ in the active site of HDACs. We sought to identify novel, nonhydroxamate-based HDAC inhibitors with potentially distinct pharmaceutical properties via an ultra-high throughput small molecule biochemical screen against the HDAC activity in a HeLa cell nuclear extract. An alpha-mercaptoketone series was identified and chemically optimized. The lead compound, KD5170, exhibits HDAC inhibitory activity with an IC50 of 0.045 micromol/L in the screening biochemical assay and an EC50 of 0.025 micromol/L in HeLa cell-based assays that monitor histone H3 acetylation. KD5170 also exhibits broad spectrum classes I and II HDAC inhibition in assays using purified recombinant human isoforms. KD5170 shows significant antiproliferative activity against a variety of human tumor cell lines, including the NCI-60 panel. Significant tumor growth inhibition was observed after p.o. dosing in human HCT-116 (colorectal cancer), NCI-H460 (non-small cell lung carcinoma), and PC-3 (prostate cancer) s.c. xenografts in nude mice. In addition, a significant increase in antitumor activity and time to end-point occurred when KD5170 was combined with docetaxel in xenografts of the PC-3 prostate cancer cell line. The biological and pharmaceutical profile of KD5170 supports its continued preclinical and clinical development as a broad spectrum anticancer agent.


Subject(s)
Antineoplastic Agents/pharmacology , Enzyme Inhibitors/pharmacology , Histone Deacetylase Inhibitors , Pyridines/pharmacology , Sulfonamides/pharmacology , Animals , Cell Line, Tumor , Colorectal Neoplasms/drug therapy , Drug Screening Assays, Antitumor , Female , Humans , Inhibitory Concentration 50 , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Prostatic Neoplasms/drug therapy , Xenograft Model Antitumor Assays
4.
Tetrahedron ; 63(28): 6506-6511, 2007 Jul 09.
Article in English | MEDLINE | ID: mdl-18612332

ABSTRACT

The reaction of carboxylic acids with carbodiimides is reviewed, and an "introverted" carboxylic acid is proposed as a means of trapping reactive intermediates along the reaction pathway. The introverted acid is a cavitand with the carboxylic function directed toward the floor of the cavity. Its reaction with diisopropyl carboodiimide gives a covalent adduct that is either the elusive O-acylisourea or the commonly encountered N-acylurea.

5.
Org Lett ; 4(3): 319-21, 2002 Feb 07.
Article in English | MEDLINE | ID: mdl-11820869

ABSTRACT

A self-folding cavitand binds quinuclidinium cation in its vase conformation and lanthanum ions in its kite conformation. Metal coordination provides a novel switching mechanism for the uptake and release of guests.


Subject(s)
Metals/chemistry , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Conformation
SELECTION OF CITATIONS
SEARCH DETAIL
...